Orexo AB (publ) (ORX.ST)
SEK 20.8
(-5.24%)
SEK 20.8
(-5.24%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 659.4 Million SEK | -19.08% |
| 2022 | 735.9 Million SEK | 3.5% |
| 2021 | 711 Million SEK | 11.85% |
| 2020 | 635.7 Million SEK | 22.6% |
| 2019 | 518.5 Million SEK | -2.92% |
| 2018 | 534.1 Million SEK | 16.13% |
| 2017 | 459.9 Million SEK | -8.86% |
| 2016 | 504.6 Million SEK | -25.38% |
| 2015 | 676.24 Million SEK | 38.61% |
| 2014 | 487.88 Million SEK | -9.6% |
| 2013 | 539.69 Million SEK | 42.85% |
| 2012 | 377.81 Million SEK | -32.79% |
| 2011 | 562.12 Million SEK | 111.36% |
| 2010 | 265.95 Million SEK | -14.63% |
| 2009 | 311.53 Million SEK | -5.13% |
| 2008 | 328.39 Million SEK | 301.35% |
| 2007 | -163.09 Million SEK | -63.87% |
| 2006 | -99.52 Million SEK | -46.16% |
| 2005 | -68.09 Million SEK | -180.95% |
| 2004 | 84.11 Million SEK | 353.61% |
| 2003 | 18.54 Million SEK | 1393.0% |
| 2002 | 1.24 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 114.4 Million SEK | -9.13% |
| 2024 Q2 | 137.9 Million SEK | 20.54% |
| 2024 Q3 | 138.1 Million SEK | 0.15% |
| 2023 Q3 | 161.9 Million SEK | 5.47% |
| 2023 Q4 | 125.9 Million SEK | -22.24% |
| 2023 FY | 595.5 Million SEK | -19.08% |
| 2023 Q2 | 153.5 Million SEK | -18.95% |
| 2023 Q1 | 189.4 Million SEK | -18.19% |
| 2022 Q1 | 145.1 Million SEK | -26.94% |
| 2022 Q2 | 176.3 Million SEK | 21.5% |
| 2022 Q3 | 182.9 Million SEK | 3.74% |
| 2022 Q4 | 231.5 Million SEK | 26.57% |
| 2022 FY | 735.9 Million SEK | 3.5% |
| 2021 FY | 711 Million SEK | 11.85% |
| 2021 Q1 | 149.9 Million SEK | -15.12% |
| 2021 Q2 | 178.8 Million SEK | 19.28% |
| 2021 Q4 | 198.6 Million SEK | 8.17% |
| 2021 Q3 | 183.6 Million SEK | 2.68% |
| 2020 Q3 | 165.4 Million SEK | -4.06% |
| 2020 Q1 | 121.1 Million SEK | -21.41% |
| 2020 FY | 635.7 Million SEK | 22.6% |
| 2020 Q2 | 172.4 Million SEK | 42.36% |
| 2020 Q4 | 176.6 Million SEK | 6.77% |
| 2019 Q2 | 117.1 Million SEK | -20.82% |
| 2019 Q3 | 99.4 Million SEK | -15.12% |
| 2019 Q4 | 154.1 Million SEK | 55.03% |
| 2019 FY | 518.5 Million SEK | -2.92% |
| 2019 Q1 | 147.9 Million SEK | -10.2% |
| 2018 Q3 | 139.6 Million SEK | 19.62% |
| 2018 FY | 534.1 Million SEK | 16.13% |
| 2018 Q2 | 116.7 Million SEK | 3.18% |
| 2018 Q4 | 164.7 Million SEK | 17.98% |
| 2018 Q1 | 113.1 Million SEK | 2.26% |
| 2017 Q3 | 93.2 Million SEK | -17.89% |
| 2017 Q2 | 113.5 Million SEK | 8.72% |
| 2017 Q1 | 104.4 Million SEK | -11.0% |
| 2017 FY | 459.9 Million SEK | -8.86% |
| 2017 Q4 | 110.6 Million SEK | 18.67% |
| 2016 FY | 504.6 Million SEK | -25.38% |
| 2016 Q3 | 100.6 Million SEK | -29.25% |
| 2016 Q2 | 142.2 Million SEK | -1.73% |
| 2016 Q1 | 144.7 Million SEK | -39.78% |
| 2016 Q4 | 117.3 Million SEK | 16.6% |
| 2015 FY | 676.24 Million SEK | 38.61% |
| 2015 Q1 | 124.4 Million SEK | -1.33% |
| 2015 Q2 | 167.4 Million SEK | 34.57% |
| 2015 Q3 | 144.1 Million SEK | -13.92% |
| 2015 Q4 | 240.3 Million SEK | 66.76% |
| 2014 Q2 | 130.9 Million SEK | 29.22% |
| 2014 Q4 | 126.08 Million SEK | -2.72% |
| 2014 FY | 487.88 Million SEK | -9.6% |
| 2014 Q3 | 129.6 Million SEK | -0.99% |
| 2014 Q1 | 101.3 Million SEK | -20.61% |
| 2013 Q1 | 102.6 Million SEK | 4.79% |
| 2013 Q2 | 174.6 Million SEK | 70.18% |
| 2013 Q4 | 127.59 Million SEK | -5.27% |
| 2013 Q3 | 134.7 Million SEK | -22.85% |
| 2013 FY | 539.69 Million SEK | 42.85% |
| 2012 FY | 377.81 Million SEK | -32.79% |
| 2012 Q4 | 97.91 Million SEK | -0.7% |
| 2012 Q2 | 90.7 Million SEK | -0.11% |
| 2012 Q3 | 98.6 Million SEK | 8.71% |
| 2012 Q1 | 90.8 Million SEK | -71.31% |
| 2011 FY | 562.12 Million SEK | 111.36% |
| 2011 Q4 | 316.51 Million SEK | 210.03% |
| 2011 Q3 | 102.09 Million SEK | 41.98% |
| 2011 Q2 | 71.9 Million SEK | 0.41% |
| 2011 Q1 | 71.61 Million SEK | -27.62% |
| 2010 Q3 | 56.08 Million SEK | 3.47% |
| 2010 Q1 | 56.72 Million SEK | -28.66% |
| 2010 FY | 265.95 Million SEK | -14.63% |
| 2010 Q2 | 54.2 Million SEK | -4.44% |
| 2010 Q4 | 98.93 Million SEK | 76.39% |
| 2009 FY | 311.53 Million SEK | -5.13% |
| 2009 Q1 | 89.18 Million SEK | -14.42% |
| 2009 Q2 | 78.5 Million SEK | -11.97% |
| 2009 Q3 | 64.33 Million SEK | -18.05% |
| 2009 Q4 | 79.51 Million SEK | 23.59% |
| 2008 Q3 | 57.31 Million SEK | 0.0% |
| 2008 Q4 | 104.2 Million SEK | 81.81% |
| 2008 FY | 328.39 Million SEK | 301.35% |
| 2007 FY | -163.09 Million SEK | -63.87% |
| 2006 FY | -99.52 Million SEK | -46.16% |
| 2005 FY | -68.09 Million SEK | -180.95% |
| 2004 FY | 84.11 Million SEK | 353.61% |
| 2003 FY | 18.54 Million SEK | 1393.0% |
| 2002 FY | 1.24 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | -4876.979% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | -1623.381% |
| BioGaia AB (publ) | 507.08 Million SEK | -30.037% |
| Enzymatica AB (publ) | 79.92 Million SEK | -725.023% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | -1625.004% |
| Gabather AB (publ) | 9.47 Million SEK | -6860.101% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | -4330.261% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | -2301.049% |
| Nanexa AB (publ) | 135.78 Million SEK | -385.631% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | -2089.897% |
| ODI Pharma AB | -5.00 SEK | 13188000100.0% |
| Probi AB (publ) | 208.93 Million SEK | -215.604% |
| Swedencare AB (publ) | 1.12 Billion SEK | 41.532% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 92.983% |
| Toleranzia AB | 6.97 Million SEK | -9357.831% |
| Vivesto AB | 355.71 Million SEK | -85.372% |